PFIZER SAYS its experimental pill for COVID-19 cut rates of hospitalization and death by nearly 90% among patients with mild-to-moderate infections. The company announced Friday, Nov. 5, it will soon ask the U.S. Food and Drug Administration and international regulators to authorize its pill, which is taken twice a day for five days. / AP FILE PHOTO/MARK LENNIHAN
WASHINGTON (AP) – Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% in high-risk adults, as the drugmaker joined the race for an easy-to-use medication to treat the coronavirus. Currently most COVID-19 treatments require an IV or injection. Competitor Merck’s COVID-19 pill is already…
Want to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.
